New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
04:55 EDTATHN, ATHN, JNJ, JNJ, CERN, CERN, UNH, UNH, SNY, SNY, PFE, PFE, MDT, MDT, CAH, CAH, BCR, BCR, AGTC, AGTCPiper Jaffray to hold a summit
3rd Annual Heartland Summit to be held in Minneapolis on August 6-7.
News For ATHN;BCR;CAH;MDT;PFE;SNY;UNH;CERN;JNJ;AGTC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
March 23, 2015
09:03 EDTJNJLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
08:06 EDTPFEPfizer, Eli Lilly to resume Phase 3 chronic pain program for Tanezumab
Pfizer (PFE) and Eli Lilly and Company (LLY) announced that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200M upfront payment from Lilly in accordance with their collaboration agreement. This announcement follows a decision by the U.S. FDA to lift the partial clinical hold on the tanezumab development program after a review of a robust body of nonclinical data characterizing the sympathetic nervous system response to tanezumab. The data were submitted to the FDA in February. In the prior clinical studies of more than 11,000 patients, tanezumab demonstrated clinically meaningful efficacy vs. placebo and other select commonly used pain medicines. A partial clinical hold has been in place for tanezumab and all other anti-nerve growth factor antibodies since December 2012 due to adverse changes in the sympathetic nervous system of mature animals. Studies in terminal cancer pain were allowed to proceed.
08:05 EDTPFEPfizer, Eli Lilly to resume Phase 3 chronic pain program for Tanezumab
Subscribe for More Information
07:36 EDTPFEPfizer should rise 'significantly' over next two years, says Jefferies
Jefferies analyst Jeffrey Holford told investors this morning that he expects shares of Pfizer (PFE) to appreciate "significantly" over the next two years. A survey of U.S. oncologists indicated the company's Ibrance drug will be used in 50% of first line hormonal therapy within one year, with off-label use in all lines of therapy including adjuvant, Holford noted. He thinks peak sales of the drug could top $13B, which is well above consensus. In addition, the analyst views Pfizer's Global Established Pharmaceutical business as being underappreciated by the market. Potential value creating options for the pharmaceutical giant include spinning off its GEP unit by 2017 and accretive acquisitions, with possible takeover targets being Shire (SHPG), Actavis (ACT), AstraZeneca (AZN) and GlaxoSmithKline (GSK), in the eyes of Holford. He added the stock to the firm's Franchise Picks list, which encompasses its best ideas. He also raised his price target for Pfizer to $45 from $42. The stock closed Friday up 10c to $34.25.
March 20, 2015
13:03 EDTPFEPfizer says oral tofacitinib meets primary endpoint in Phase 3 trials
Subscribe for More Information
08:18 EDTUNHLeerink healthcare services analyst holds an analyst/industry conference call
Healthcare Services Analyst Gupte discusses Sustainable Growth Rate (SGR) and the proposed pay-fors and implications For Healthcare Services on an Analyst/Industry conference call to be held on March 20 at 11 am.
07:55 EDTPFEAstraZeneca seen as potential target again if oncology drugs lag, Bloomberg says
Subscribe for More Information
07:41 EDTPFEAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
06:11 EDTBCRC.R. Bard management to meet with Leerink
Subscribe for More Information
March 19, 2015
11:00 EDTPFEPfizer participates in a conference call with Bernstein
Subscribe for More Information
10:02 EDTCERNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:18 EDTAGTCGlobal Technology Community to hold a conference
7th Ocular Diseases Drug Discovery Conference is being held in San Diego, California on March 19-20.
07:09 EDTSNYSanofi reports top-line results for Lyxumia for cardiovascular safety
Sanofi announced top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, which compared lixisenatide to placebo in a high-risk population of adults with type 2 diabetes evaluating cardiovascular safety. The study showed that lixisenatide was non-inferior, although not superior, to placebo for cardiovascular safety. The results will be included in the U.S. New Drug Application of lixisenatide, which is on track to be resubmitted to the FDA in Q3. Lixisenatide is not approved in the U.S.
06:15 EDTATHNathenahealth coverage transferred with an Outperform at RW Baird
Subscribe for More Information
05:30 EDTSNYSanofi reports lixisenatide was non-inferior, though not superior to placebo
Subscribe for More Information
March 18, 2015
17:09 EDTPFEPfizer CAPiTA published in New England Journal of Medicine
Subscribe for More Information
16:06 EDTCERNCerner upgraded to Outperform from Neutral at RW Baird
Subscribe for More Information
09:33 EDTCERNCerner selected by Washington hospitals to update health record systems
The State of Washington Department of Social and Health Services has selected health IT supplier Cerner to modernize integrated revenue cycle and electronic health records in multiple state facilities to prepare for ICD-10 compliance. The agreement will digitize DSHS' paper health records. Cerner will implement Millennium PowerChart and the revenue cycle suite of solutions at three accredited psychiatric hospitals, including Western State Hospital, Eastern State Hospital and Child Studies and Treatment Center. Cerner will replace the billing functionality supported by the Residential Programs System, as well as the central pharmacy system. DSHS' system will be hosted at Cerner's Kansas City data center.
09:32 EDTSNYMannKind faces cash shortfall if $100M debt not settled, TheStreet says
Subscribe for More Information
05:39 EDTMDTSt. Jude Medical downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded St. Jude Medical (STJ) to Market Perform saying competitive pressures will drive 2015 market share losses in the company's cardiac rhythm management business, which represents 50% of total sales. Wells believes the launch of CardioMEMS will not be strong enough to offset the headwinds in CRM unit. The firm thinks Boston Scientific's (BSX) earlier than expected approval for its next generation subcutaneous implantable cardioverter-defibrillator called Emblem will drive share gains against St. Jude and Medtronic (MDT) in the single chamber ICD market. Wells cut its price target range for St. Jude shares to $69-$70 from $73-$74. The medical technology company closed yesterday down $2.01 to $65.45.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use